Oncology

Blood test may identify patients who need more intensive chemotherapy.

Teikoku Pharma USA has submitted a New Drug Application to the FDA for the product.

Current smokers and those who quit less than 10 years prior to surgery face twice the risk of disease recurrence.

Genetic changes in tumors linked to immune system response to disease.

Costs have risen 120% in aggregate since 1995.

Formic acid from stinging nettles and ants greatly increases treatment's ability to shut down cancer cells.

Errors in genes may leave tumors susceptible to PARP inhibitors.

Treatment increases immune response with fewer side effects.

Nanoscale treatment could potentially eliminate cancer cells without harming surrounding tissue.

Emerging technology could help patients make better decisions regarding whether to undergo aggressive prostate cancer treatment.

Discovery may lead to new treatment designs.

Risk of sudden onset menopause reduced by adding goserelin to chemotherapy regimen.

Treatment can selectively drop medication at the site of tumors.

Survivors of breast cancer more likely to develop aggressive form of thyroid cancer.

Study finds older patients and minorities less likely to receive treatment.

Study finds depression in African American cancer patients has gone under-recognized.

Combination therapy treats patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.

Average period to disease recurrence same as with placebo.

Dinutuximab approved as part of a regimen that includes surgery, chemotherapy, and radiation therapy.

Economic variables impact breast cancer treatment, study finds.

The FDA today approved the first available treatment option for patients with high-risk neuroblastoma.

Supplemental oxygenation may shrink tumors and enhance cancer immunotherapy.

Taste pathway changes in patients on chemotherapy for basal cell carcinoma.

Study argues for more balanced information for patients before making a treatment decision.

Biosimilars are finally a reality in the US drug market, but a report warns regulatory decisions may limit future savings from the drugs.

FDA approves Zarxio for the same indications as Neupogen.

After years of debate and regulatory hurdles, a milestone was achieved today when the FDA approved the first biosimilar in the United States.

Patients receiving chemotherapy after surgery had a 30% lower risk of death than those who had surgery alone.

Since patients with Barrett's esophagus seem to progress to cancerous stages faster than others, health care professionals might perceive that controlling acid reflux would prevent the transition.

Opdivo was originally approved for patients with unresectable or metastatic melanoma who no longer respond to other drugs.